AI assistant
MetaVia Inc. — Director's Dealing 2017
Mar 14, 2017
34919_dirs_2017-03-14_f890beec-b84e-4590-80a6-506bd902c63c.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Gemphire Therapeutics Inc. (GEMP)
CIK: 0001638287
Period of Report: 2017-03-10
Reporting Person: Gullans Steven R. Ph.D. (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2017-03-10 | Common Stock | P | 52798 | $9.47 | Acquired | 858823 | Indirect |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2017-03-10 | Warrant to Purchase Common Stock | $10.4 | P | 39599 | Acquired | 2022-03-15 | Common Stock (39599) | Indirect |
Footnotes
F1: The shares of common stock and warrants were purchased as part of a private placement pursuant to a Securities Purchase Agreement whereby the Issuer sold units consisting of one share of the Issuer's common stock and a warrant to purchase 0.75 shares of the Issuer's common stock at a per unit price of $9.47. The private placement is expected to close on March 15, 2017.
F2: The reporting person, as the Manager of Excel Venture Fund II, L.P., beneficially owns the reported securities indirectly, but disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.